Dr. Kelley on the Development of Biomarkers for HCC

R. Kate Kelley, MD
Published: Wednesday, Jun 07, 2017



R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses the development of biomarkers for patients with hepatocellular carcinoma (HCC).

The potential of many therapies in development depends on identifying the patient groups most likely to benefit, explains Kelley. This will require a better understanding of the biology of HCC.

According to Kelley, the potential of new therapies will drive a wave of research to further define the relevant subgroups.
 


R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses the development of biomarkers for patients with hepatocellular carcinoma (HCC).

The potential of many therapies in development depends on identifying the patient groups most likely to benefit, explains Kelley. This will require a better understanding of the biology of HCC.

According to Kelley, the potential of new therapies will drive a wave of research to further define the relevant subgroups.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x